share_log

Abbott Laboratories | 10-Q: Q2 2024 Earnings Report

Abbott Laboratories | 10-Q: Q2 2024 Earnings Report

雅培 | 10-Q：2024财年二季报
美股SEC公告 ·  2024/08/01 04:06

Moomoo AI 已提取核心信息

Abbott Laboratories reported Q2 2024 net sales of $10.4 billion, up 4.0% year-over-year, with organic growth of 7.5% excluding foreign exchange impact. Medical Devices segment led growth with a 10.2% increase to $4.7 billion, driven by FreeStyle Libre continuous glucose monitoring system sales of $3.0 billion in H1. Net earnings were $1.3 billion with diluted EPS of $0.74.The company saw strong performance across segments, with Nutritional Products up 3.5% and Established Pharmaceuticals up 0.6%. However, Diagnostic Products declined 5.3% to $2.2 billion due to lower COVID-19 testing demand, with COVID-19 testing sales dropping to $102 million from $263 million in Q2 2023. Gross margin improved to 51.1% from 50.1% last year.Abbott maintained its financial strength with $7.0 billion in cash and equivalents as of June 30, 2024. The company increased its quarterly dividend by 7.8% to $0.55 per share and received key regulatory approvals, including FDA clearance for new over-the-counter continuous glucose monitoring systems and FDA approval for the Esprit BTK system and TriClip tricuspid valve repair device.
Abbott Laboratories reported Q2 2024 net sales of $10.4 billion, up 4.0% year-over-year, with organic growth of 7.5% excluding foreign exchange impact. Medical Devices segment led growth with a 10.2% increase to $4.7 billion, driven by FreeStyle Libre continuous glucose monitoring system sales of $3.0 billion in H1. Net earnings were $1.3 billion with diluted EPS of $0.74.The company saw strong performance across segments, with Nutritional Products up 3.5% and Established Pharmaceuticals up 0.6%. However, Diagnostic Products declined 5.3% to $2.2 billion due to lower COVID-19 testing demand, with COVID-19 testing sales dropping to $102 million from $263 million in Q2 2023. Gross margin improved to 51.1% from 50.1% last year.Abbott maintained its financial strength with $7.0 billion in cash and equivalents as of June 30, 2024. The company increased its quarterly dividend by 7.8% to $0.55 per share and received key regulatory approvals, including FDA clearance for new over-the-counter continuous glucose monitoring systems and FDA approval for the Esprit BTK system and TriClip tricuspid valve repair device.
雅培在2024年第二季度报告净销售额为104亿美金，同比增长4.0%，在不考虑汇率影响的情况下，归因于7.5%的有机增长。医疗设备部门引领增长，增加了10.2%，达到47亿美金，主要受益于在上半年销售的FreeStyle Libre连续血糖监测系统的30亿美金。净收益为13亿美金，摊薄后每股收益为0.74美金。该公司在各个部门的表现都很强劲，营养产品增长了3.5%，成熟药品增长了0.6%。然而，诊断产品因COVID-19检测需求下降，下降了5.3%，降至22亿美金，COVID-19检测销售额从2023年第二季度的26300万美金降至10200万美金。毛利率从去年的50.1%提高到51.1%。截...展开全部
雅培在2024年第二季度报告净销售额为104亿美金，同比增长4.0%，在不考虑汇率影响的情况下，归因于7.5%的有机增长。医疗设备部门引领增长，增加了10.2%，达到47亿美金，主要受益于在上半年销售的FreeStyle Libre连续血糖监测系统的30亿美金。净收益为13亿美金，摊薄后每股收益为0.74美金。该公司在各个部门的表现都很强劲，营养产品增长了3.5%，成熟药品增长了0.6%。然而，诊断产品因COVID-19检测需求下降，下降了5.3%，降至22亿美金，COVID-19检测销售额从2023年第二季度的26300万美金降至10200万美金。毛利率从去年的50.1%提高到51.1%。截至2024年6月30日，雅培维持了70亿美金的现金和现金等价物的财务实力。该公司将季度股息提高了7.8%，达到每股0.55美金，并获得了关键的监管批准，包括FDA对新型非处方连续血糖监测系统的许可以及FDA对Esprit BTk系统和TriClip三尖瓣修复设备的批准。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间